Eurofins Viracor Launches Ground-Breaking Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients
February 16 2023 - 1:15AM
Business Wire
Eurofins Viracor ExPeCT™ CAR-T multiplexed
quantitative real-time PCR (qPCR) assay provides a powerful
diagnostic tool to monitor and optimise CAR-T therapy involving
patients with pre-B cell acute lymphoblastic leukemia and B cell
lymphomas
Eurofins (Paris:ERF):
Eurofins Viracor LLC, part of the Eurofins network of companies,
and a leader in testing for infectious disease, immunology, and
allergy, today announces the launch of a ground-breaking test that
can assess the expansion and persistence of Chimeric Antigen
Receptor T-Cell (CAR-T) therapy in patients with pre-B cell acute
lymphoblastic leukemia and B cell lymphomas.
The test, based on a method developed by Eurofins Viracor, is
designed to help clinicians better understand how CAR-T therapy is
performing for their patients. CAR-T therapy is a revolutionary
form of immunotherapy that uses genetically engineered T-cells to
attack cancer cells and has shown promising results in treating a
variety of cancers.
Research has demonstrated that the persistence and expansion of
CAR-T therapy are important indicators of how long the therapy is
likely to remain effective in the patient. The test is designed to
provide clinicians with an accurate and comprehensive assessment of
the CAR-T cell population in the patient’s body and may offer
insights to therapy effectiveness.
The launch of this test marks an important step forward in the
evaluation and management of CAR-T therapy in cancer patients. It
is expected to be a valuable tool in helping clinicians to make
more informed decisions about the best course of treatment for
their patients.
Notes to Editors:
About Eurofins– the global leader in bio-analysis
Eurofins is Testing for Life. With 61,000 staff across a network of
940 laboratories in 59 countries, Eurofins’ companies offer a
portfolio of over 200,000 analytical methods. Eurofins Shares are
listed on Euronext Paris Stock Exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230215005674/en/
For more information, please visit www.eurofins.com or
contact:
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620
E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024